Corporate strategy

Proprietary technology driving next generation diagnostics:

- Unique biomarker signatures to increase the specificity & sensitivity of in vitro diagnostic tests

- Increased ability to predict & monitor patients response to therapy

- Detection of minimal residual disease & early relapse

Partnership model to deliver business success:

- Corporate partnerships to accelerate uptake in clinical & pharmaceutical markets

- A strong advisory board with proven track record of science & innovation

- An extensive network of clinical collaborators

Recent pilot experiments by ProteinLogic Ltd indicate the potential of their unique biomarker 'signatures' to revolutionise clinical diagnosis and patient management. The company has early patent allowance & has built an internationally-renowned Scientific Advisory Board and a strong management team. Early funding has already been achieved.

Following new investment to complete extended proof-of-principle, validated clinical 'signatures' will be progressively out-licensed to strategic partners. These partners have already been identified and will provide an early and low risk route to the target markets, while ensuring high margin, high growth revenue streams.